Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

601 A

Next Previous
Drug Profile

601 A

Alternative Names: 601; 601-A; 601A-AMD; 601A-DME; 601A-pmCNV; 601A-RVO; Anti-VEGF monoclonal antibody - Sunshine Guojian Pharmaceutical

Latest Information Update: 28 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3SBio
  • Developer 3SBio; Sunshine Guojian Pharmaceutical
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic macular oedema
  • Phase II Choroidal neovascularisation
  • No development reported Age-related macular degeneration; Wet age-related macular degeneration

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in China (Parenteral, Injection)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Wet age-related macular degeneration(Treatment-experienced) in China (Intravitreous, Injection)
  • 27 Dec 2022 Phase-III clinical trials in Diabetic macular oedema in China (Intravitreous) (NCT05520177)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top